Thomas Ahlering, Orange, CA INTRODUCTION AND OBJECTIVES: We previously reported a new post radical prostatectomy (RP) prediction model for men with normal baseline erectile function (EF) using 90-d postoperative erection fullness to identify men who might benefit from early EF rehabilitation. We seek to prospectively internally and externally validate the use of this risk assessment model in predicting 1-and 2-yr post-RP EF recovery.
INTRODUCTION AND OBJECTIVES:
We previously reported a new post radical prostatectomy (RP) prediction model for men with normal baseline erectile function (EF) using 90-d postoperative erection fullness to identify men who might benefit from early EF rehabilitation. We seek to prospectively internally and externally validate the use of this risk assessment model in predicting 1-and 2-yr post-RP EF recovery.
METHODS: We randomly assigned 297 patients with a preoperative International Index of Erectile Function 5 score of 22 to 25 undergoing robot-assisted RP by a single surgeon to a training set and internal validation set at a ratio of 2:1. A prospective external validation set included 91 patients treated by five high volume surgeons. Potency was defined as erections sufficient for intercourse. To predict 1-and 2-yr potency recovery, logistic regression models were developed in the training set based on 90-d erection fullness of 0 to 24% or 25 to 100%. The resultant models were applied to the internal and external validation sets to calculate risk scores for 1-and 2-yr potency for each patient. Predictive validity was assessed using receiver operating characteristic (ROC) curves.
RESULTS: Percentage erection fullness was an independent predictor of 1-and 2-yr potency recovery in all data sets. Internal validation confirmed strong reliability in predicting 2-yr potency outcomes (area under the ROC curve [AUC] 0.87) and external validation illustrated similar reliability in predicting 1-yr potency outcomes (AUC 0.80). In the external validation, the model predicted a mean 1-yr potency recovery rate of 39.7% (standard deviation 3.2%), compared to the actual rate of 36.26%.
CONCLUSIONS: We present internal and external validation of a 90-d percentage erection fullness score, confirming that this metric is a robust predictor of post-RP EF recovery.
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MP40-11 LONGITUDINAL EVALUATION OF FREQUENCY OF PATIENTS TAKING PART IN SEXUAL INTERCOURSE AND SEXUAL ACTIVITIES AFTER UNDERGOING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY
Shogo Inoue*, Tetsutaro Hayashi, Jun Teishima, Akio Matsubara, Hiroshima, Japan INTRODUCTION AND OBJECTIVES: Erectile dysfunction significantly affects health-related quality of life. Even if a patient can function sexually after radical prostatectomy, he may not be able to take part in sexual intercourse; thus, sexual function may be perceived to have decreased. We evaluated the frequency of sexual intercourse and sexual activities of patients after undergoing robotassisted laparoscopic radical prostatectomy (RALP).
METHODS: We prospectively obtained one-year longitudinal the Expanded Prostate Cancer Index Composite (EPIC) data (preoperative and at 3, 6, 9, and 12 months after RALP) from 300 patients. We classified the frequency of sexual intercourse and activities as "Not at all", "Less than once a week", "About once a week", "Several times a week", and "Daily".
RESULTS:
The percentages of patients who took part in sexual activity before undergoing RALP and 3, 6, 9, and 12 months after RALP were 47, 23, 29, 31, and 34%, respectively. Those of patients who took part in sexual intercourse before undergoing RALP and 3, 6, 9, and 12 months after RALP were 33, 6, 10, 10, and 10%, respectively. Both sets of values after undergoing RALP were significantly lower than those before undergoing RALP (Fig.1) . Sexual activity was not associated with the improvement of sexual function in Sexual Health Inventory for Men (SHIM) score. On the other hand, sexual activity was associated with the improvement of sexual function in EPIC score as with sexual intercourse (Fig.2) .
CONCLUSIONS: There was a large discrepancy between the percentages of patients taking part in sexual intercourse and sexual other activities; therefore, we should consider not only sexual intercourse but also sexual activities when evaluating normal sexual function in patients with localized prostate cancer after RALP. (FDC116115; NCT01777269) showing a significant reduction (worsening) in total MSHQ scores with dutasteride/tamsulosin fixed-dose combination therapy (DUT-TAM FDC) compared with placebo. No minimal clinically meaningful difference has been established for the MSHQ. The objective of this analysis was to evaluate the clinical relevance of total and subdomain MSHQ score changes by association with sexual AEs of special interest (AESIs) reported in the same study.
METHODS: This was a post hoc analysis of study FDC116115, which enrolled sexually active men aged !50 years with a diagnosis of BPH across 51 sites who were randomized 1:1 to receive oral DUT-TAM FDC (DUT 0.5 mg, TAM 0.4 mg, once daily) or placebo for 12 months. The cumulative distribution function for change from baseline in MSHQ total and domain scores was assessed. A MantelHaenszel test stratified by treatment was used to evaluate the association between worsening of MSHQ scores from baseline to month 12 with corresponding occurrence of sexual AESIs.
RESULTS: 489 patients were randomized n[243; placebo, n[246) . Cumulative distribution plots for MSHQ total and domain scores at month 12 showed larger reductions in total MSHQ and ejaculation domain scores with DUT-TAM FDC than placebo. There was minimal difference between the groups in the plots for erection, sexual satisfaction, and desire domain scores. The majority of patients spontaneously reporting any sexual AESI (86% DUT-TAM FDC, 67% placebo) had a worsening of their MSHQ total score at month 12; this association was significant (P<.001) across both treatment groups. Patients treated with DUT-TAM FDC were more likely to report any sexual AESI at a threshold reduction of w10 points in total MSHQ score from baseline to month 12. Overall, most patients across both groups reporting ejaculation and erection AESIs, had worsening of the equivalent MSHQ domain score at month 12 (88%, P[.002 and 78%, P<.001, respectively).
CONCLUSIONS: A reduction in the total MSHQ score was associated with greater likelihood of a sexual AESI, warranting further investigation. A clinically-relevant MSHQ threshold will enable clinicians to anticipate and proactively address potential sexual side effects of BPH therapy.
